人免疫球蛋白、川芎嗪治疗过敏性紫癜的临床观察

Clinical observation of human immunoglobulin and ligustrazine in the treatment of allergic purpura

目的:探讨人免疫球蛋白、川芎嗪治疗过敏性紫癜的疗效与安全性。方法:收治过敏性紫癜患者126例,随机分为观察组86例和对照组40例,两组均按常规治疗,抗过敏、应用维生素C及钙剂等。观察组在此基础上应用人免疫球蛋白静滴400 mg/(kg·d),疗程3 d;盐酸川芎嗪2~4 mg/(kg·d)。结果:观察组总有效率96.5%,对照组总有效率80%,差异有统计学意义,P<0.01。结论:人免疫球蛋白、盐酸川芎嗪是治疗过敏性紫癜的安全有效药物。

Objective:To discuss the efficacy and safety of human immunoglobulin and ligustrazine in the treatment of allergic purpura.Methods:126 patients with allergic purpura were selected.They were randomly divided into the observation group with 86 cases,the control group with 40 cases.Two groups were used conventional therapy,anti-allergy,such as vitamin C and calcium.The observation group was intravenous infusion immunoglobulin 400 mg/(kg·d) on this basis,the duration were 3d;ligustrazine hydrochloride 2~4 mg/(kg·d).Results:The total efficiency of the observation group was 96.5%;the control group was 80%;there was statistically significant P<0.01.Conclusion:Human Immunoglobulin,ligustrazine hydrochloride are the effective and safe drug in the treatment of allergic purpura.